Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00596154 · OUTCOME

Overall Response Rates

Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma · Source last updated 2024-04-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
after 10 weeks (5 cycles)

What was measured

To evaluate response rates with the combination of rituximab and MPV as induction chemotherapy.

Groups in this outcome

Newly Diagnosed Primary CBS Lymphoma/PCNSL

Rituximab, methotrexate (MTX), procarbazine and vincristine (R-MPV). The peripheral blood stem cell (PBSC) harvest procedure will be performed at the discretion of the hematology attending. Participants will be off study at the time of death.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Newly Diagnosed Primary CBS Lymphoma/PCNSL33

Reported measurements

Source class 1

Progression Free

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Newly Diagnosed Primary CBS Lymphoma/PCNSL1Not reportedNot reportedNot reportedNot reported

Complete Response

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Newly Diagnosed Primary CBS Lymphoma/PCNSL22Not reportedNot reportedNot reportedNot reported

Partial Response

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Newly Diagnosed Primary CBS Lymphoma/PCNSL6Not reportedNot reportedNot reportedNot reported

Stable Disease

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Newly Diagnosed Primary CBS Lymphoma/PCNSL1Not reportedNot reportedNot reportedNot reported

Not Evaluable

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Newly Diagnosed Primary CBS Lymphoma/PCNSL3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      title
      Progression Free
    2. measurements
      1. group Id
        OG000
        value
        22
      title
      Complete Response
    3. measurements
      1. group Id
        OG000
        value
        6
      title
      Partial Response
    4. measurements
      1. group Id
        OG000
        value
        1
      title
      Stable Disease
    5. measurements
      1. group Id
        OG000
        value
        3
      title
      Not Evaluable
denoms
  1. counts
    1. group Id
      OG000
      value
      33
    units
    Participants
description
To evaluate response rates with the combination of rituximab and MPV as induction chemotherapy.
groups
  1. description
    Rituximab, methotrexate (MTX), procarbazine and vincristine (R-MPV). The peripheral blood stem cell (PBSC) harvest procedure will be performed at the discretion of the hematology attending. Participants will be off study at the time of death.
    id
    OG000
    title
    Newly Diagnosed Primary CBS Lymphoma/PCNSL
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
after 10 weeks (5 cycles)
title
Overall Response Rates
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice